medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Number 5

<< Back Next >>

Rev Invest Clin 2018; 70 (5)

Dyslipidemia in Mexico, a Call for Action

Rivas-Gomez B, Almeda-Valdés P, Tussié-Luna MT, Aguilar-Salinas CA

Language: English
References: 30
Page: 211-216
PDF size: 81.01 Kb.


ABSTRACT

The purpose of this manuscript is to highlight the peculiarities of the Mexican population regarding the clinical expression, genetics, and treatment of lipid disorders. Furthermore, it is a call for action to address the existing gaps in care and research of dyslipidemias. The Mexican Mestizos are highly susceptible to metabolic disorders (i.e., low high-density lipoprotein cholesterol concentrations, hypertriglyceridemia, abdominal obesity, and type 2 diabetes); these conditions are associated with ethnicspecific genetic variants. On the other hand, despite the high prevalence of dyslipidemia in Mexican adults, there is a lack of awareness of these conditions. The public is not informed about the need for screening and the potential benefit of the lipidlowering treatments. Underdiagnosis and undertreatment are two of the main challenges to be solved. Dyslipidemias are not among the priorities of the health systems for the prevention of cardiovascular disease; access to laboratory resources and medications is insufficient in primary care units despite the proven cost-benefit of the treatment of lipid disorders. Evidencebased public policies are needed to change the practice and allocation of assets to be capable of preventing cardiovascular diseases. Treatment of dyslipidemia should have a prominent role in any effort to decrease the number of preventable deaths caused by non-communicable diseases.


REFERENCES

  1. Garcia-Garcia G, Aviles-Gomez R, Luquin-Arellano VH, et al. Cardiovascular risk factors in the Mexican population. Ren Fail. 2006;28:677-87.

  2. Villarreal-Molina MT, Aguilar-Salinas CA, Rodríguez-Cruz M, et al. The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes. 2007;56:1881-7.

  3. Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Campos O, et al. Association of the ATP-binding cassette transporter A1 R230C variant with early-onset Type 2 diabetes in a Mexican population. Diabetes. 2008;57:509-13.

  4. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A, et al. Metabolic syndrome in Mexican adults: results from the national health and nutrition survey 2006. Salud Publica Mex. 2010;52 Suppl 1:S11-8.

  5. SSA. Encuesta Nacional de Enfermedades Crónicas 1993. México, D.F: Secretaría de Salud; 1994.

  6. Aguilar-Salinas CA, Olaiz G, Valles V, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42:1298-307.

  7. Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, et al. Prevalence of dyslipidemias in the Mexican national health and nutrition survey 2006. Salud Publica Mex. 2010;52 Suppl 1:S44-53.

  8. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for Type 2 diabetes and other cardiovascular risk factors in Mexico from 1993-2006. Salud Publica Mex. 2010;52 Suppl 1:S72-9.

  9. Aguilar-Salinas CA, Tusie-Luna T, Pajukanta P. Genetic and environmental determinants of the susceptibility of Amerindian derived populations for having hypertriglyceridemia. Metabolism. 2014;63:887-94.

  10. Escobedo-de la Peña J, de Jesús-Pérez R, Schargrodsky H, Champagne B. Prevalencia de dislipidemias en la ciudad de México y su asociación con otros factores de riesgo cardiovascular. Resultados del estudio CARMELA. Gac Med Mex. 2014;150:128-36.

  11. Vinueza R, Boissonnet CP, Acevedo M, et al. Dyslipidemia in seven Latin American cities: CARMELA study. Prev Med. 2010; 50:106-11.

  12. Aguilar-Salinas C, Canizales-Quinteros S, Rojas-Martínez R, Mehta R, Villarreal-Molina M, Arellano-Campos O. Hypoalphalipoproteinemia in populations of native American ancestry: an opportunity to assess the interaction of genes and the environment. Curr Opin Lipidol. 2009;20:92-7.

  13. Solís-Olivares CA, Muñoz-Cardona M. Prevalencia de factores de riesgo cardiovascular en pacientes evaluados por dolor torácico. Rev Mex Cardiol. 2007;18:109-18.

  14. Bibiloni MD, Salas R, De la Garza YE, et al. Serum lipid profile, prevalence of dyslipidaemia, and associated risk factors among northern Mexican adolescents. J Pediatr Gastroenterol Nutr. 2016;63:544-9.

  15. Dron JS, Hegele RA. Genetics of triglycerides and the risk of atherosclerosis. Curr Atheroscler Rep. 2017;19:31.

  16. Ko A, Cantor RM, Weissglas-Volkov D, et al. Amerindian-specific regions under positive selection harbour new lipid variants in Latinos. Nat Commun. 2014;5:3983.

  17. Suárez-Sánchez F, Klunder-Klunder M, Valladares-Salgado A, et al. APOA5 and APOA1 polymorphisms are associated with triglyceride levels in Mexican children. Pediatr Obes. 2017;12 330-6.

  18. Parra EJ, Mazurek A, Gignoux CR, et al. Admixture mapping in two mexican samples identifies significant associations of locus ancestry with triglyceride levels in the BUD13/ZNF259/APOA5 region and fine mapping points to rs964184 as the main driver of the association signal. PLoS One. 2017;12:e0172880.

  19. Aguilar-Salinas CA, Sevilla González MD, Tusie-Luna MT. Searching for the causal variants of the association between hypertriglyceridemia and the genome-wide association studies-derived signals? Take a look in the native American populations. Circ Cardiovasc Genet. 2017;10:pii:e002010.

  20. Aguilar Salinas CA, Zamora M, Gómez-Díaz RA, et al. Familial combined hyperlipidemia: controversial aspects of its diagnosis and pathogenesis. Semin Vasc Med. 2004;4:203-9.

  21. Huertas-Vázquez A, del Rincón J, Canizales-Quinteros S, et al. Contribution of chromosome 1q21-q23 to familial combined hyperlipidemia in Mexican families. Ann Human Genet. 2004; 68:419-27.

  22. Suviolahti E, Lilja HE, Pajukanta P. Unraveling the complex genetics of familial combined hyperlipidemia. Ann Med. 2006; 38:337-51.

  23. Weissglas-Volkov D, Plaisier C, Huertas-Vázquez A, et al. Identification of two common variants contributing to serum apolipoprotein B levels in Mexicans. Arterioscler Thromb Vasc Biol. 2009;30:353-9.

  24. Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, et al. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis. 2015;243:257-9.

  25. Robles-Osorio L, Huerta-Zepeda A, Ordóñez ML Canizales- Quinteros S, Díaz-Villaseñor A, Gutiérrez-Aguilar R, et al. Genetic heterogeneity of autosomal dominant hypercholesterolemia in Mexico. Arch Med Res. 2006;37:102-8.

  26. Vaca G, Vázquez A, Magaña M, Ramírez M, Dávalos I, Martínez E. Mutational analysis of the LDL receptor and APOB genes in Mexican individuals with autosomal dominant hypercholesterolemia. Atherosclerosis. 2011;218:391-6.

  27. Mehta R, Zubirán R, Martagón A, et al. The panorama of familial hypercholesterolemia in Latin America: a systematic review. J Lipid Res. 2016;57:2115-29.

  28. Santos R, Bourbon M, Alonso R, et al. Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries. J Clin Lipidol. 2017;11:160-6.

  29. Vallejo-Vaz A, Akram A, Seshasai SK, et al. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS familial hypercholesterolaemia studies collaboration. Atheroscler Suppl. 2016;22:1-32.

  30. Rivera-Hernández M, Galárraga O. Type of insurance and use of preventive health services among older adults in Mexico. J Aging Health. 2015;27: 62-982.




2020     |     www.medigraphic.com